Blair V Landon
Overview
Explore the profile of Blair V Landon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shaikh F, Lee S, White J, Zhao Y, Ferri J, Pereira G, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518082
: Preclinical and clinical data indicate that chemoradiotherapy (CRT) in combination with checkpoint inhibitors may prime an anti-tumor immunological response in esophageal cancer. However, responses to neoadjuvant therapy can vary...
2.
Kelly R, Landon B, Zaidi A, Singh D, Canzoniero J, Balan A, et al.
Nat Med
. 2024 Mar;
30(4):1023-1034.
PMID: 38504015
Gastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual programmed cell death protein 1 (PD-1) and lymphocyte-activation gene...
3.
Sivapalan L, Iams W, Belcaid Z, Scott S, Niknafs N, Balan A, et al.
Clin Cancer Res
. 2023 Apr;
29(12):2310-2323.
PMID: 37071497
Purpose: Patients with small-cell lung cancer (SCLC) have an exceptionally poor prognosis, calling for improved real-time noninvasive biomarkers of therapeutic response. Experimental Design: We performed targeted error-correction sequencing on 171...
4.
Anagnostou V, Landon B, Medina J, Forde P, Velculescu V
Sci Transl Med
. 2022 Nov;
14(670):eabo3958.
PMID: 36350985
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics, triggering studies to understand the molecular and cellular wiring of response and resistance. Our increased understanding of the underlying biology of response...
5.
Scharpf R, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, et al.
Cancer Res
. 2022 Sep;
82(21):4058-4078.
PMID: 36074020
Significance: The complex genomic landscape of RAS-mutant tumors is reflective of selection processes in a cancer lineage-specific and context-dependent manner, highlighting differential therapeutic vulnerabilities that can be clinically translated.